Navigation Links
Arpida Announces Agenda Items for Shareholders Meeting
Date:4/15/2008

REINACH, Switzerland, April 15 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today published the agenda for the Annual General Meeting of Shareholders, to be held in Basel on 7 May 2008. The invitation appears today in several Swiss media and will be sent to all registered Arpida shareholders. The agenda is available on the website http://www.arpida.com.

Apart from the yearly recurring agenda items, Arpida's Board of Directors will put two additional proposals to the shareholders.

The first additional agenda item relates to the proposed appointment of Elmar Schnee to the Board of Directors.

Elmar Schnee is a highly experienced Pharma executive who has gathered a wealth of international experience at several large and small pharmaceutical companies. He is currently President of Merck Serono S.A. and Regular Member of the Executive Board and General Partner of Merck KGaA, with responsibility for the Pharmaceuticals business sector. Mr Schnee is a Swiss national.

The terms of three current Arpida Board members expire in the AGM of 7 May 2008 and all three will stand for re-election. Professor Nam-Hai Chua, a Board member since 2004, has resigned from the Board.

The second additional proposal is aimed at increasing Arpida's flexibility in terms of potential financing instruments. In the past, Arpida's funds have primarily been provided by equity investors through the issue of shares. Going forward, Arpida may consider alternative sources of funding such as, for instance, convertible bonds.

In order to create the possibility to issue such instruments, the Company will ask its shareholders to make the necessary changes to its Articles of Association. If the shareholders' meeting approves these changes, Arpida will have the possibility to issue a total of no more than 3.2 million shares (15% of the currently outstanding share capital), either via a straight equity issue (authorised capital) or via conversion of bonds (conditional capital). Arpida currently has no intention to use this capital. This proposed additional capital cannot be used for the granting of employee options.

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent antibacterial that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The clinical programme for the first indication, complicated skin and skin structure infections (cSSSI), has been completed. The submission of the NDA to the US FDA was completed in March 2008.

In December 2007, Arpida announced the enrolment of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In January 2008, the US FDA granted authorisation to progress oral iclaprim into a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch could be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is in Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Arpida contacts:

Dr Khalid Islam, President and CEO Tel: +41-61-417-96-60

Harry Welten, MBA, CFO and Senior Vice President Tel: +41-61-417-96-65

Paul Verbraeken, Head of Corporate Communications Tel: +41-61-417-96-83


'/>"/>
SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
2. Arpida Announces Full Year 2007 Financial Results
3. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
4. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
5. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
6. Arpida-Supported CME Symposium Available Online
7. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
8. Arpida Presents Preclinical Data on AR-2474 at ICAAC
9. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
10. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
11. Arpida Interim Results for six Months to 30 June 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , Mar 23, 2017 Research ... Products: Global Markets" report to their offering. ... The Global ... $466.6 Billion in 2016 at a CAGR of 8.9%, ... energetic and non-energetic bioproducts into seven major product segments: bio-derived ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ellen Matloff, president and CEO ... (CTC) as a 2017 Women of Innovation® finalist. Matloff will be among several ... , The dinner recognizes women accomplished in science, technology, engineering and math (STEM), ...
(Date:3/23/2017)... 2017 In today,s pre-market research, ... the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate ... SYN), and Regulus Therapeutics Inc. (NASDAQ: RGLS ... Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn ... at: ...
(Date:3/22/2017)... 22, 2017  UBM and the Massachusetts Medical ... extended partnership and the third annual Massachusetts Medtech Week. ... 21 st Annual MassMEDIC Conference held in ... 3-4, 2017. MassMEDIC will feature ... President and CEO, Scott Whitaker , at ...
Breaking Biology Technology:
(Date:3/6/2017)... , March 6, 2017 Mintigo ... technology, today announced Predictive Sales Coach TM , ... actionable sales intelligence into Salesforce. This unique AI ... their sales organizations with deep knowledge of their ... for intelligent engagement. Predictive Sales Coach extends Mintigo,s ...
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ... Iris-Scan, wird seine erstklassige biometrische Lösung zur ... 835 mit X16 LTE auf dem Mobile ... März) am Qualcomm-Stand in Halle 3, Stand ... beinhaltet die Sicherheitsplattform Qualcomm Haven™ – eine ...
Breaking Biology News(10 mins):